Diabetes Mellitus, Type 2 study: Insulin icodec vs Basal insulin analogues
Official title A Research Study to See How Well Weekly Insulin Icodec Maintains Blood Sugar Levels Compared to Daily Basal Insulins in Adults With Type 2 Diabetes
ClinicalTrials.gov ID: NCT07112339
What this study is testing
What is Insulin icodec?
Insulin icodec is an investigational medicine, given as a once-weekly injection under the skin, being studied as a potential treatment for diabetes mellitus, type 2.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study aims to find out how well weekly insulin icodec keeps blood sugar stable compared with daily basal insulins.
- Who it's for
- Adults who have type 2 diabetes.
- What's involved
- Participants will be given either weekly insulin icodec or a daily basal insulin (such as insulin glargine, detemir, or degludec) and will follow the usual injection schedule with regular check‑ups and blood‑sugar tests.
- Time commitment
- The trial lasts about 13 months and includes periodic clinic visits for monitoring and testing.
- Phase 4: studies an already-approved treatment
- Time commitment: about 13 months
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Diagnosed with T2D greater than or equal to (≥) 180 days prior to the day of screening.
- Treatment with any of the following non-insulin glucose-lowering medication(s) or combination regimen(s) at the time of screening: Metformin...
- Need of intensification with basal insulin, as indicated at the discretion of the investigator.
- Recorded HbA1c value ≥7% within the last 90 days prior to randomization.
You likely can't join if
- Known or suspected hypersensitivity to study intervention(s) or related products.
- Previous participation in this study. Participation is defined as signed informed consent.
- Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using adequate contraceptive method.
- Participation (i.e., received any study intervention) in any treatment clinical study within 90 days before screening.
- Any disorder which in the investigator's opinion might jeopardize participant's safety.
The study team makes the final eligibility decision.
Where it is enrolling
- Calgary, Alberta, Canada
- Edmonton, Alberta, Canada
- New Westminster, British Columbia, Canada
- Winnipeg, Manitoba, Canada
- Moncton, New Brunswick, Canada
- Brampton, Ontario, Canada
- Concord, Ontario, Canada
- Etobicoke, Ontario, Canada
- Greater Sudbury, Ontario, Canada
- Hamilton, Ontario, Canada
- London, Ontario, Canada
- Nepean, Ontario, Canada
- Toronto, Ontario, Canada
- Joliette, Quebec, Canada
- Lévis, Quebec, Canada
- Mirabel, Quebec, Canada
- Montreal, Quebec, Canada
- Pointe-Claire, Quebec, Canada
- Sherbrooke, Quebec, Canada
- Terrebonne, Quebec, Canada
+ 31 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The study runs about 13 months per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Calgary, Alberta, Canada; Edmonton, Alberta, Canada; New Westminster, British Columbia, Canada; Winnipeg, Manitoba, Canada; Moncton, New Brunswick, Canada; Brampton, Ontario, Canada and 45 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.